Skip to navigation bar Skip to breadcrumbs Skip to page content
Envelope icon E-mail Updates Teal square Text size:  a A A

Menopausal Hormone Therapy: Preventive Medication

Release Date: October 2012

Recommendation Summary

Summary of Recommendations and Evidence

PopulationRecommendationGrade
(What's This?)
Postmenopausal Women

The USPSTF recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits
Postmenopausal Women, Who Have Had a Hysterectomy

The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy.

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits

This recommendation applies only to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. This is not a recommendation about the use of hormone therapy to treat menopausal symptoms, such as hot flashes or vaginal dryness; the USPSTF did not review the evidence related to this possible indication because it falls outside of the mission and scope of the USPSTF. This recommendation also does not apply to women younger than 50 years who have had surgical menopause.

 

Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: September 2013

Internet Citation: Recommendation Summary. U.S. Preventive Services Task Force. September 2014.
http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/menopausal-hormone-therapy-preventive-medication

USPSTF Program Office   540 Gaither Road, Rockville, MD 20850